KTN's online platform helps you to make the connections you need


The Knowledge Transfer Network (KTN) has refreshed its online platform to intelligently connect you to relevant events, funding, thought pieces and specialist staff to help your business innovate and grow.

You can discover content using your area of interest, from Defence Security to transport; from space to health – all major UK economic sectors are covered. Once you have selected your interests, using our intelligent tagging system, we will then display rich and relevant content related to your area, often from surprising sources.

An example might be new satellite technology from the space sector that is applicable in the agri-food sector. KTN-UK.co.uk will help you form these unusual and valuable connections.

All content on the platform has been carefully curated by our team of innovation specialists – not by an automated algorithm – so you can be confident that KTN is connecting you to the most relevant cutting-edge information.


The move also marks a closer alignment with our main funder, Innovate UK , with the website branding making a clear visual link. Knowledge Transfer Network is Innovate UK's innovation network partner, and also works with other funders to provide innovation networking services and fulfil our mission to drive UK growth.

We link new ideas and opportunities with expertise, markets and finance through our network of businesses, universities, funders and investors. From agri-food to autonomous systems and from energy to design, KTN combines expertise in all sectors with the ability to cross boundaries. Connecting with KTN can lead to potential partners, horizon-expanding events and innovation insights relevant to your needs.

Visit our people pages to connect directly with expertise in your sector.

Visit the KTN refreshed online platfom here

« go back

Daiichi Sankyo Webinar

UKTI Japan Life Sciences Team are delighted to announce Japanese pharmaceutical company webinar, by inviting the speaker from Daiichi-Sankyo Co Ltd on Tuesday 21st  October, 09:30am (UK time) / 17:30 (Japan time).
Daiichi Sankyo Co Ltd is Japan’s 3rd largest research based pharmaceutical company with sales of USD 11.1 billion dollars (GBP 6.9 billion pounds) in fiscal year 2013. It was established in 2005 by the merger of two 100-year-old Japanese pharmaceutical companies.
Daiichi Sankyo is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. While maintaining its portfolio of marketed pharmaceuticals for hypertension, dyslipidemia and bacterial infections used by patients around the world, the Group has also launched treatments for thrombotic disorders and is building new product franchises.
Furthermore, Daiichi Sankyo research and development is focused on bringing forth novel therapies in oncology, cardiovascular-metabolic diseases and products with novel mechanisms of action, including biologics.
Daiichi Sankyo partners on promising products that complement its in-house portfolio and will achieve long-term growth. The company’s  strategy involves acquiring new products and product candidates, and companies that will drive their portfolio in key therapeutic areas.  Daiichi Sankyo has a long-history of effective collaboration, exemplifying its ability to license products in and out of the company while developing and maintaining valuable partnerships throughout the industry.
For more information, please visit the company website at http://www.daiichisankyo.com/
At this webinar, Mr. Yuichi Kubo, Vice President, Business Development and Licensing will explain about the overview of  Daiichi Sankyo’s business and partnering strategy and areas of potential collaboration opportunities.
Daiichi Sankyo is participating at Bio-Europe Frankfurt, Germany (November 3-5, 2014) as a sponsor.  This webinar will provide an opportunity to understand their visions for future partnering and collaboration opportunities in advance for the Europe’s largest partnering conference.
Daiichi Sankyo is happy to have meetings with prospective UK business partners at the Daiichi Sankyo partnering suite during Bio-Europe.
Please don’t miss this rare opportunity to identify your potential business with Daiichi Sankyo and register via Export to Japan website by clicking the button or through the URL below.  Please note that this event is only open to the UK based companies.
Register here
“Learning from top performers in the Japanese pharmaceutical market: Daiichi Sankyo Co., Ltd:  Strategies for future partnering and collaboration with the UK companies”
Tuesday 21 October
9:30-10:15, UK Time (Presentation and Q&A)
Online event
Mr. Yuichi Kubo, Vice President, Business Development and LicensingDaiichi Sankyo Co., Ltd.
Mr. Yuichi Kubo started his business carrier at Daiichi Pharmaceutical Co., Ltd. in 1980. He worked in areas of global regulatory affairs and clinical development in Japan (diabetes and asthma). He was based in London from 1990-1996 as a project manager for clinical development in Europe (mainly anti-bacterials). After returning to Japan, he became responsible for implementing new Japanese GCP process and related computer systems. He then worked for global regulatory affairs, document management, medial writing and GCP management. At the integration of Daiichi and Sankyo, he was appointed as VP, Head of Development Research of US subsidiary, coordinating non-clinical and pharmaceutical development activities, followed by the role of Vice President for Translational Medicine and Clinical Pharmacology in Japan, and from 2012 Global Head of Intellectual Property. He is appointed to the current position as of April 2014. He was trained as a biochemist and holds master degree in pharmaceutical science.
Benefits of participation:   
This webinar will explain:
·         Japan’s major pharmaceutical company’s strategy for product development
·         Areas of possible collaboration between Daiichi Sankyo Co., Ltd. and your company
You will have the opportunity to interact with the speaker by asking  text questions during the Q&A session.